Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A multi-country, multicenter, randomized, open-label, parallel group study to assess the efficacy and safety of Docecal compared with Taxotere®

    Summary
    EudraCT number
    2012-005161-12
    Trial protocol
    LV  
    Global end of trial date
    11 Jan 2018

    Results information
    Results version number
    v1(current)
    This version publication date
    04 Aug 2019
    First version publication date
    04 Aug 2019
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    OAS-12DOC-BIO
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Oasmia Pharmaceutical AB
    Sponsor organisation address
    Vallongatan 1, Uppsala, Sweden, SE-752 28
    Public contact
    Oasmia Pharmaceutical AB , Oasmia Pharmaceutical AB , info@oasmia.com
    Scientific contact
    Head of Clinical Development, Oasmia Pharmaceutical AB , nina.heldring@oasmia.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    17 Oct 2018
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    11 Jan 2018
    Global end of trial reached?
    Yes
    Global end of trial date
    11 Jan 2018
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective is to demonstrate that Docecal is not inferior to Taxotere®, measured as overall response rate (ORR).
    Protection of trial subjects
    An independent medical monitor reviewed safety data during the study. Laboratory measurements (haematology and clinical chemistry), vital signs and physical examination were assessed to monitor safety of patients. Patients were withdrawn if medically necessary according to investigator.
    Background therapy
    -
    Evidence for comparator
    Taxotere is a well known anticancer treatment that has been approved on the market for breast cancer for several decades. Both Taxotere and the test drug contain the same active molecule and the only difference between the formulations are the excipients.
    Actual start date of recruitment
    11 Mar 2016
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Russian Federation: 120
    Country: Number of subjects enrolled
    Ukraine: 80
    Worldwide total number of subjects
    200
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    163
    From 65 to 84 years
    37
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Screening was performed maximum 21 days before first dose. Criteria included female with adenocarcinoma of breast who had failed anthracycline treatment, age ≥18 years, ECOG ≤2 . 15 of 217 screened patients did not meet inclusion/exclusion criteria and 2 patients withdraw their consent before randomization.

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Docecal
    Arm description
    Patients randomized to receive Docecal.
    Arm type
    Experimental

    Investigational medicinal product name
    Docecal
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Docecal was administered as 1-hour intravenous infusion at a dose of 100 mg/m2 docetaxel every 21 days for a total of 6 cycles. The dose was calculated based on body surface area. The powder was reconstituted to a concentration of 0.5 mg/ml using NaCl solution before infusion. No dexamethasone premedication was required, unless hypersensitivity reactions or fluid retention occurred during the study.

    Arm title
    Taxotere
    Arm description
    Patients randomized to receive Taxotere.
    Arm type
    Active comparator

    Investigational medicinal product name
    Taxotere
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Taxotere was administered as 1-hour intravenous infusion at a dose of 100 mg/m2 docetaxel every 21 days for a total of 6 cycles. The dose was calculated based on body surface area. The powder was reconstituted according to Taxotere´s SmPC before infusion. Dexamethasone premedication was given at a dose of 16 mg/day (8 mg twice per day) for 3 days starting 1 day prior docetaxel administration.

    Number of subjects in period 1
    Docecal Taxotere
    Started
    100
    100
    Completed
    79
    80
    Not completed
    21
    20
         Adverse event, serious fatal
    -
    2
         Consent withdrawn by subject
    1
    2
         Physician decision
    4
    2
         Other illness that prevents further treatment
    1
    -
         Adverse event, non-fatal
    2
    3
         Death
    1
    1
         Inability to follow treatment schedule
    1
    -
         Patient´s condition
    2
    -
         Lost to follow-up
    -
    2
         Lack of efficacy
    9
    8

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Docecal
    Reporting group description
    Patients randomized to receive Docecal.

    Reporting group title
    Taxotere
    Reporting group description
    Patients randomized to receive Taxotere.

    Reporting group values
    Docecal Taxotere Total
    Number of subjects
    100 100 200
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    82 81 163
        From 65-84 years
    18 19 37
        85 years and over
    0 0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    54.9 ( 10.2 ) 56.2 ( 8.3 ) -
    Gender categorical
    Units: Subjects
        Female
    100 100 200
        Male
    0 0 0
    Body surface area
    Units: m2
        arithmetic mean (standard deviation)
    1.76 ( 0.18 ) 1.80 ( 0.15 ) -

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Docecal
    Reporting group description
    Patients randomized to receive Docecal.

    Reporting group title
    Taxotere
    Reporting group description
    Patients randomized to receive Taxotere.

    Primary: Overall response rate (partial and complete response) after 6 cycles of chemotherapy

    Close Top of page
    End point title
    Overall response rate (partial and complete response) after 6 cycles of chemotherapy
    End point description
    Overall response rate (partial and complete response) after 6 cycles of chemotherapy, based on the assessments of the Independent Imaging Review Facility according to RECIST 1.1 criteria (2009).
    End point type
    Primary
    End point timeframe
    CT/MR scans were performed at baseline (within 28 days prior to the start of treatment) and every 9 weeks ± 3 days after the date of randomization
    End point values
    Docecal Taxotere
    Number of subjects analysed
    100
    100
    Units: patients
        Complete response
    1
    3
        Partial response
    30
    42
        Stable disease
    53
    42
        Disease progression
    9
    9
        Not evaluable
    7
    4
    Statistical analysis title
    Non-inferiority testing
    Statistical analysis description
    The primary endpoint was analyzed by a non-inferiority test using the Farrington-Manning method. The criterion for non-inferiority at final analysis is considered to have been met if the lower limit of the 1-sided 97.36% confidence interval for the difference in ORR between groups (test drug – reference drug) is above the predefined non-inferiority margin -23%.
    Comparison groups
    Docecal v Taxotere
    Number of subjects included in analysis
    200
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    Method
    Parameter type
    Difference in ORR (Docecal-Taxotere)
    Point estimate
    -14
    Confidence interval
         level
    97.36%
         sides
    1-sided
         lower limit
    -27
         upper limit
    -

    Post-hoc: Overall response rate (partial and complete repsonse) at end of chemotherapy visit (Visit 16/Day 127+7)

    Close Top of page
    End point title
    Overall response rate (partial and complete repsonse) at end of chemotherapy visit (Visit 16/Day 127+7)
    End point description
    Overall response rate (partial and complete response) at the end of chemotherapy visit (Visit 16/Day 127+7) based on the assessments of the Independent Imaging Review Facility
    End point type
    Post-hoc
    End point timeframe
    CT/MR scans were performed at baseline (within 28 days prior to the start of treatment) and every 9 weeks ± 3 days after the date of randomization
    End point values
    Docecal Taxotere
    Number of subjects analysed
    100
    100
    Units: patients
        Complete response
    1
    2
        Partial response
    26
    33
        Stable disease
    30
    28
        Disease progression
    19
    14
        Neither complete response nor progressive disease
    2
    2
        Not evaluable
    1
    1
        Missing (no tumour assessment at visit 16)
    21
    20
    Statistical analysis title
    Non-inferiority testing
    Statistical analysis description
    Non-inferiority test using the Farrington-Manning method. The criterion for non-inferiority at final analysis is considered to have been met if the lower limit of the 1-sided 97.36% confidence interval for the difference in ORR between groups (test drug – reference drug) is above the predefined non-inferiority margin -23%.
    Comparison groups
    Docecal v Taxotere
    Number of subjects included in analysis
    200
    Analysis specification
    Post-hoc
    Analysis type
    non-inferiority
    Method
    Parameter type
    Difference in ORR (Docecal-Taxotere)
    Point estimate
    -8
    Confidence interval
         level
    97.36%
         sides
    1-sided
         lower limit
    -20.4
         upper limit
    -

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Reporting period started on the first day of protocol therapy and ended when the patient left the study, whether prematurely or at the end of study.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    20.0
    Reporting groups
    Reporting group title
    Docecal
    Reporting group description
    Patients randomized to receive Docecal.

    Reporting group title
    Taxotere
    Reporting group description
    Patients randomized to receive Taxotere.

    Serious adverse events
    Docecal Taxotere
    Total subjects affected by serious adverse events
         subjects affected / exposed
    57 / 98 (58.16%)
    87 / 100 (87.00%)
         number of deaths (all causes)
    1
    3
         number of deaths resulting from adverse events
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Tumour haemorrhage
         subjects affected / exposed
    1 / 98 (1.02%)
    0 / 100 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Coronary artery insufficiency
         subjects affected / exposed
    0 / 98 (0.00%)
    1 / 100 (1.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Nervous system disorders
    Central pain syndrome
         subjects affected / exposed
    1 / 98 (1.02%)
    0 / 100 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Headache
         subjects affected / exposed
    1 / 98 (1.02%)
    0 / 100 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Neutropenia
         subjects affected / exposed
    51 / 98 (52.04%)
    83 / 100 (83.00%)
         occurrences causally related to treatment / all
    151 / 151
    256 / 256
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Leukopenia
         subjects affected / exposed
    15 / 98 (15.31%)
    27 / 100 (27.00%)
         occurrences causally related to treatment / all
    27 / 27
    43 / 43
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Febrile neutropenia
         subjects affected / exposed
    14 / 98 (14.29%)
    23 / 100 (23.00%)
         occurrences causally related to treatment / all
    15 / 15
    24 / 24
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Anaemia
         subjects affected / exposed
    0 / 98 (0.00%)
    1 / 100 (1.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    1 / 98 (1.02%)
    0 / 100 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Death
         subjects affected / exposed
    0 / 98 (0.00%)
    1 / 100 (1.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Immune system disorders
    Hypersensitivity
         subjects affected / exposed
    0 / 98 (0.00%)
    1 / 100 (1.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    1 / 98 (1.02%)
    0 / 100 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    1 / 98 (1.02%)
    0 / 100 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    2 / 98 (2.04%)
    0 / 100 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abscess soft tissue
         subjects affected / exposed
    0 / 98 (0.00%)
    1 / 100 (1.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Erysipelas
         subjects affected / exposed
    0 / 98 (0.00%)
    1 / 100 (1.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Frequency threshold for reporting non-serious adverse events: 2%
    Non-serious adverse events
    Docecal Taxotere
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    98 / 98 (100.00%)
    100 / 100 (100.00%)
    Vascular disorders
    Phlebitis
         subjects affected / exposed
    11 / 98 (11.22%)
    0 / 100 (0.00%)
         occurrences all number
    12
    0
    Phlebitis superficial
         subjects affected / exposed
    4 / 98 (4.08%)
    0 / 100 (0.00%)
         occurrences all number
    5
    0
    Hypertension
         subjects affected / exposed
    1 / 98 (1.02%)
    2 / 100 (2.00%)
         occurrences all number
    2
    2
    Thrombophlebitis
         subjects affected / exposed
    2 / 98 (2.04%)
    1 / 100 (1.00%)
         occurrences all number
    7
    1
    Lymphostasis
         subjects affected / exposed
    2 / 98 (2.04%)
    0 / 100 (0.00%)
         occurrences all number
    2
    0
    Vascular pain
         subjects affected / exposed
    2 / 98 (2.04%)
    0 / 100 (0.00%)
         occurrences all number
    3
    0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    44 / 98 (44.90%)
    50 / 100 (50.00%)
         occurrences all number
    91
    89
    Oedema peripheral
         subjects affected / exposed
    28 / 98 (28.57%)
    18 / 100 (18.00%)
         occurrences all number
    37
    21
    Face oedema
         subjects affected / exposed
    21 / 98 (21.43%)
    21 / 100 (21.00%)
         occurrences all number
    23
    25
    Fatigue
         subjects affected / exposed
    11 / 98 (11.22%)
    16 / 100 (16.00%)
         occurrences all number
    22
    36
    Pyrexia
         subjects affected / exposed
    4 / 98 (4.08%)
    12 / 100 (12.00%)
         occurrences all number
    5
    12
    Injection site phlebitis
         subjects affected / exposed
    13 / 98 (13.27%)
    0 / 100 (0.00%)
         occurrences all number
    43
    0
    Injection site thrombosis
         subjects affected / exposed
    9 / 98 (9.18%)
    0 / 100 (0.00%)
         occurrences all number
    20
    0
    Injection site erythema
         subjects affected / exposed
    6 / 98 (6.12%)
    0 / 100 (0.00%)
         occurrences all number
    7
    0
    Peripheral swelling
         subjects affected / exposed
    1 / 98 (1.02%)
    4 / 100 (4.00%)
         occurrences all number
    1
    4
    Oedema
         subjects affected / exposed
    2 / 98 (2.04%)
    2 / 100 (2.00%)
         occurrences all number
    2
    2
    Hyperthermia
         subjects affected / exposed
    3 / 98 (3.06%)
    0 / 100 (0.00%)
         occurrences all number
    5
    0
    Localised oedema
         subjects affected / exposed
    1 / 98 (1.02%)
    2 / 100 (2.00%)
         occurrences all number
    1
    3
    Influenza like illness
         subjects affected / exposed
    2 / 98 (2.04%)
    0 / 100 (0.00%)
         occurrences all number
    2
    0
    Injection site discolouration
         subjects affected / exposed
    2 / 98 (2.04%)
    0 / 100 (0.00%)
         occurrences all number
    2
    0
    Injection site pain
         subjects affected / exposed
    2 / 98 (2.04%)
    0 / 100 (0.00%)
         occurrences all number
    6
    0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    0 / 98 (0.00%)
    4 / 100 (4.00%)
         occurrences all number
    0
    4
    Hydrothorax
         subjects affected / exposed
    4 / 98 (4.08%)
    0 / 100 (0.00%)
         occurrences all number
    4
    0
    Cough
         subjects affected / exposed
    0 / 98 (0.00%)
    3 / 100 (3.00%)
         occurrences all number
    0
    4
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    25 / 98 (25.51%)
    28 / 100 (28.00%)
         occurrences all number
    39
    42
    Aspartate aminotransferase increased
         subjects affected / exposed
    21 / 98 (21.43%)
    27 / 100 (27.00%)
         occurrences all number
    33
    35
    Blood bilirubin increased
         subjects affected / exposed
    5 / 98 (5.10%)
    13 / 100 (13.00%)
         occurrences all number
    8
    20
    Blood alkaline phosphatase increased
         subjects affected / exposed
    5 / 98 (5.10%)
    10 / 100 (10.00%)
         occurrences all number
    7
    17
    Blood chloride increased
         subjects affected / exposed
    2 / 98 (2.04%)
    12 / 100 (12.00%)
         occurrences all number
    5
    13
    Blood sodium decreased
         subjects affected / exposed
    3 / 98 (3.06%)
    8 / 100 (8.00%)
         occurrences all number
    10
    11
    Blood calcium decreased
         subjects affected / exposed
    2 / 98 (2.04%)
    6 / 100 (6.00%)
         occurrences all number
    4
    8
    Blood magnesium increased
         subjects affected / exposed
    1 / 98 (1.02%)
    6 / 100 (6.00%)
         occurrences all number
    1
    8
    Blood magnesium decreased
         subjects affected / exposed
    3 / 98 (3.06%)
    2 / 100 (2.00%)
         occurrences all number
    7
    3
    Blood uric acid increased
         subjects affected / exposed
    1 / 98 (1.02%)
    4 / 100 (4.00%)
         occurrences all number
    1
    5
    Blood creatine increased
         subjects affected / exposed
    2 / 98 (2.04%)
    2 / 100 (2.00%)
         occurrences all number
    2
    3
    Electrocardiogram abnormal
         subjects affected / exposed
    1 / 98 (1.02%)
    3 / 100 (3.00%)
         occurrences all number
    1
    3
    Blood urea increased
         subjects affected / exposed
    2 / 98 (2.04%)
    1 / 100 (1.00%)
         occurrences all number
    2
    2
    Electrocardiogram repolarisation abnormality
         subjects affected / exposed
    0 / 98 (0.00%)
    3 / 100 (3.00%)
         occurrences all number
    0
    3
    Weight increased
         subjects affected / exposed
    2 / 98 (2.04%)
    1 / 100 (1.00%)
         occurrences all number
    2
    1
    Cardiac disorders
    Sinus tachycardia
         subjects affected / exposed
    3 / 98 (3.06%)
    3 / 100 (3.00%)
         occurrences all number
    3
    3
    Pericardial effusion
         subjects affected / exposed
    2 / 98 (2.04%)
    1 / 100 (1.00%)
         occurrences all number
    2
    1
    Defect conduction intraventricular
         subjects affected / exposed
    0 / 98 (0.00%)
    2 / 100 (2.00%)
         occurrences all number
    0
    2
    Nervous system disorders
    Peripheral sensory neuropathy
         subjects affected / exposed
    11 / 98 (11.22%)
    25 / 100 (25.00%)
         occurrences all number
    11
    26
    Dysgeusia
         subjects affected / exposed
    8 / 98 (8.16%)
    11 / 100 (11.00%)
         occurrences all number
    13
    22
    Hypoaesthesia
         subjects affected / exposed
    4 / 98 (4.08%)
    7 / 100 (7.00%)
         occurrences all number
    7
    7
    Headache
         subjects affected / exposed
    3 / 98 (3.06%)
    2 / 100 (2.00%)
         occurrences all number
    3
    3
    Neuropathy peripheral
         subjects affected / exposed
    3 / 98 (3.06%)
    3 / 100 (3.00%)
         occurrences all number
    3
    3
    Polyneuropathy
         subjects affected / exposed
    1 / 98 (1.02%)
    5 / 100 (5.00%)
         occurrences all number
    1
    6
    Hypogeusia
         subjects affected / exposed
    1 / 98 (1.02%)
    2 / 100 (2.00%)
         occurrences all number
    1
    4
    Somnolence
         subjects affected / exposed
    0 / 98 (0.00%)
    2 / 100 (2.00%)
         occurrences all number
    0
    2
    Syncope
         subjects affected / exposed
    0 / 98 (0.00%)
    2 / 100 (2.00%)
         occurrences all number
    0
    2
    Blood and lymphatic system disorders
    Neutropenia
         subjects affected / exposed
    76 / 98 (77.55%)
    85 / 100 (85.00%)
         occurrences all number
    241
    219
    Leukopenia
         subjects affected / exposed
    77 / 98 (78.57%)
    93 / 100 (93.00%)
         occurrences all number
    299
    374
    Anaemia
         subjects affected / exposed
    34 / 98 (34.69%)
    35 / 100 (35.00%)
         occurrences all number
    69
    62
    Febrile neutropenia
         subjects affected / exposed
    1 / 98 (1.02%)
    0 / 100 (0.00%)
         occurrences all number
    1
    0
    Thrombocytopenia
         subjects affected / exposed
    13 / 98 (13.27%)
    10 / 100 (10.00%)
         occurrences all number
    23
    19
    Hypoglobulinaemia
         subjects affected / exposed
    2 / 98 (2.04%)
    5 / 100 (5.00%)
         occurrences all number
    6
    9
    Thrombocytosis
         subjects affected / exposed
    2 / 98 (2.04%)
    1 / 100 (1.00%)
         occurrences all number
    4
    2
    Eye disorders
    Eyelid oedema
         subjects affected / exposed
    2 / 98 (2.04%)
    1 / 100 (1.00%)
         occurrences all number
    2
    1
    Lacrimation increased
         subjects affected / exposed
    0 / 98 (0.00%)
    3 / 100 (3.00%)
         occurrences all number
    0
    3
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    30 / 98 (30.61%)
    17 / 100 (17.00%)
         occurrences all number
    79
    43
    Diarrhoea
         subjects affected / exposed
    20 / 98 (20.41%)
    25 / 100 (25.00%)
         occurrences all number
    29
    35
    Stomatitis
         subjects affected / exposed
    13 / 98 (13.27%)
    21 / 100 (21.00%)
         occurrences all number
    24
    43
    Vomiting
         subjects affected / exposed
    9 / 98 (9.18%)
    2 / 100 (2.00%)
         occurrences all number
    10
    4
    Dry mouth
         subjects affected / exposed
    3 / 98 (3.06%)
    7 / 100 (7.00%)
         occurrences all number
    5
    10
    Abdominal pain upper
         subjects affected / exposed
    0 / 98 (0.00%)
    3 / 100 (3.00%)
         occurrences all number
    0
    5
    Abdominal pain
         subjects affected / exposed
    0 / 98 (0.00%)
    2 / 100 (2.00%)
         occurrences all number
    0
    3
    Hepatobiliary disorders
    Hyperbilirubinaemia
         subjects affected / exposed
    3 / 98 (3.06%)
    2 / 100 (2.00%)
         occurrences all number
    4
    2
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    39 / 98 (39.80%)
    60 / 100 (60.00%)
         occurrences all number
    44
    71
    Erythema
         subjects affected / exposed
    2 / 98 (2.04%)
    10 / 100 (10.00%)
         occurrences all number
    3
    16
    Nail discolouration
         subjects affected / exposed
    4 / 98 (4.08%)
    7 / 100 (7.00%)
         occurrences all number
    4
    8
    Nail disorder
         subjects affected / exposed
    0 / 98 (0.00%)
    4 / 100 (4.00%)
         occurrences all number
    0
    4
    Pruritus
         subjects affected / exposed
    3 / 98 (3.06%)
    0 / 100 (0.00%)
         occurrences all number
    3
    0
    Dermatitis allergic
         subjects affected / exposed
    0 / 98 (0.00%)
    2 / 100 (2.00%)
         occurrences all number
    0
    2
    Erythema multiforme
         subjects affected / exposed
    0 / 98 (0.00%)
    2 / 100 (2.00%)
         occurrences all number
    0
    2
    Onychoclasis
         subjects affected / exposed
    0 / 98 (0.00%)
    2 / 100 (2.00%)
         occurrences all number
    0
    2
    Rash
         subjects affected / exposed
    0 / 98 (0.00%)
    2 / 100 (2.00%)
         occurrences all number
    0
    2
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    7 / 98 (7.14%)
    11 / 100 (11.00%)
         occurrences all number
    22
    33
    Bone pain
         subjects affected / exposed
    2 / 98 (2.04%)
    4 / 100 (4.00%)
         occurrences all number
    7
    6
    Myalgia
         subjects affected / exposed
    1 / 98 (1.02%)
    2 / 100 (2.00%)
         occurrences all number
    1
    2
    Pain in extremity
         subjects affected / exposed
    2 / 98 (2.04%)
    0 / 100 (0.00%)
         occurrences all number
    2
    0
    Infections and infestations
    Respiratory tract infection
         subjects affected / exposed
    4 / 98 (4.08%)
    3 / 100 (3.00%)
         occurrences all number
    4
    3
    Upper respiratory tract infection
         subjects affected / exposed
    3 / 98 (3.06%)
    2 / 100 (2.00%)
         occurrences all number
    3
    2
    Erysipelas
         subjects affected / exposed
    0 / 98 (0.00%)
    3 / 100 (3.00%)
         occurrences all number
    0
    3
    Metabolism and nutrition disorders
    Hyperglycaemia
         subjects affected / exposed
    12 / 98 (12.24%)
    34 / 100 (34.00%)
         occurrences all number
    31
    92
    Decreased appetite
         subjects affected / exposed
    12 / 98 (12.24%)
    15 / 100 (15.00%)
         occurrences all number
    46
    46
    Hypoproteinaemia
         subjects affected / exposed
    4 / 98 (4.08%)
    4 / 100 (4.00%)
         occurrences all number
    7
    8
    Fluid retention
         subjects affected / exposed
    4 / 98 (4.08%)
    3 / 100 (3.00%)
         occurrences all number
    5
    4
    Hypoalbuminaemia
         subjects affected / exposed
    2 / 98 (2.04%)
    3 / 100 (3.00%)
         occurrences all number
    3
    6
    Hypocalcaemia
         subjects affected / exposed
    3 / 98 (3.06%)
    2 / 100 (2.00%)
         occurrences all number
    5
    2
    Type 2 diabetes mellitus
         subjects affected / exposed
    0 / 98 (0.00%)
    2 / 100 (2.00%)
         occurrences all number
    0
    2

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    26 Dec 2015
    The objective of Protocol amendment was to clarify an inclusion criterion, to correct the description of the main and interim analyses and safety data reporting. A new drug strength of Docecal was added (100 mg/vial). The possibility of primary prophylaxis with G-CSF to individual patients was also added.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 01:39:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA